Seattle Genetics, Inc.

Seattle Genetics' CEO Discusses Q4 2012 Results - Earnings Call Transcript

Seattle Genetics Reports Fourth Quarter and Year 2012 Financial Results

5 Stocks Poised to Pop on Bullish Earnings

SGEN Starts SGN-CD19A Phase I Study - Analyst Blog

Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A

Seattle Genetics Commences Two Phase I Trials of SGN-CD19A

Canada Approves Seattle Genetics' Adcetris - Analyst Blog

Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory H

Seattle Genetics' ADCETRIS Approved by Health Canada for Treatment of Relapsed, Refractory HL, sALCL

Data From SGEN on Cancer Candidate - Analyst Blog